CCM
ZBIO

Catalio Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Catalio Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-215,314
Closed -$2.09M – 50
2025
Q2 		$2.09M Sell
215,314
-79,834
-27% -$777K 0.44% 28
2025
Q1 		$2.33M Buy
295,148
+107,964
+58% +$845K 0.57% 26
2024
Q4 		$1.53M Buy
+187,184
New +$2.92M 0.34% 29

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalio Capital Management's ZBIO Position: Q3 2025 in Review

Catalio Capital Management sold out of Zenas BioPharma (ZBIO) in Q3 2025, closing a stake of 215,314 shares — an estimated $2.09M sold.

Catalio Capital Management first reported a position in ZBIO in Q4 2024 and held it in 3 quarters. The position peaked at $2.33M in Q1 2025. 80 funds tracked by Wall St. Rank hold ZBIO as of Q3 2025.

  • Catalio Capital Management reported no remaining Zenas BioPharma position as of Q3 2025 after selling out during the quarter.
  • Catalio Capital Management sold 215,314 Zenas BioPharma shares in Q3 2025, an estimated $2.09M.
  • Catalio Capital Management first reported a position in Zenas BioPharma in Q4 2024 and held it in 3 quarters.
  • Catalio Capital Management's Zenas BioPharma position peaked at $2.33M in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2025.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.